Imago Biosciences

Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition

Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO--Imago BioSciences Announces Its Addition to the Russell 2000® Index

Imago BioSciences Announces Its Addition to the Russell 2000® Index

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate updates. “2021 to date has been a transformative year for Imago BioSciences. We have made progress in advancing the clinical development of our lead product candidate

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common stock, the underwriters have exercised their option to purchase an additional 1,260,000 shares of common stock from the Company. The gross proceeds from the exercise of the option,

Imago BioSciences, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ImagoBioSciences--Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering

Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering

Blend Labs

Bridge Investment Group Holdings

Erasca Inc

Regencell Bioscience Holdings Ltd

Stevanato Group SpA

The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.

7 Companies Begin Trading. Here's How They're Doing.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #IMGO--Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

Imago BioSciences has filed to raise $105 million in an IPO and $20 million in a concurrent private placement. The firm is developing treatments for various bone marrow diseases.

Imago BioSciences Seeks $105 Million IPO

News for Imago Biosciences Stock (IMGO)